LakePharma

29 articles with LakePharma

• Integrity Bio and LakePharma Become Curia

  2/14/2022

  Curia, formerly AMRI, a leading contract research, development and manufacturing organization, announced that Integrity Bio and LakePharma, two companies that it acquired last year, have fully transitioned to the Curia brand.

• Curia to Acquire US-Based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics

  7/14/2021

  Curia announced it has entered into a definitive agreement to acquire LakePharma Inc., a privately held biologics drug discovery, clinical research, development and manufacturing organization with operations in California, Massachusetts, and Texas.

• LakePharma Supplying Mount Sinai with SARS-CoV-2 Proteins for Serological Assays

  5/6/2020

  LakePharma announces that the company will be supplying the Mount Sinai Health System recombinant SARS-CoV-2 spike proteins to the Mount Sinai Laboratory as a component in its blood test for antibody response against SARS-CoV-2, the virus that causes the COVID-19 pandemic.

• LakePharma and NJ Bio Form Strategic Alliance to Provide Streamlined Antibody-Drug Conjugate Services

  2/11/2020

  LakePharma, Inc., the leading US-based biologics CRDMO, and NJ Biopharmaceuticals LLC (d/b/a NJ Bio), a CRO providing integrated chemistry and biology services, today announce the formation of a strategic alliance to offer streamlined antibody-drug conjugate (ADC) development solutions for the biotech

• LakePharma Announces Its 2019 Symposium Agenda

  7/30/2019

  Distinguished Speakers to Present Latest Developments in Next-Generation Therapeutics

• LakePharma Announces Expansion into the Dallas/Fort Worth Metroplex

  7/23/2019

  The new location allows LakePharma to better align its services with clients' demands in the rapidly growing biologics industry.

• LakePharma Launches GMP Manufacturing of Recombinant Proteins and Antibodies in the Bay Area

  4/2/2019

  LakePharma, Inc., the leading US-based biologics CRDMO, announced the launch of GMP manufacturing of recombinant proteins and antibodies with CHO-GSN™ and TunaCHO™ platforms at its Hayward, California facility.

• LakePharma Announces Dedicated Vector Center to Support Gene and Cell Therapy

  2/26/2019

  The center is located in Worcester, MA, which is in close proximity to the Cambridge and Boston areas. 

• LakePharma Announces its GMP Biorepository Facility near Boston is Now Operational, Plans Additional Hiring

  1/15/2019

  LakePharma, Inc. announced that their GMP biorepository facility is now commercially operational at their Hopkinton, MA location, which is in close proximity to the Cambridge and Boston areas.

• LakePharma announces its cGMP microBiomanufacturing Center is now operational

  12/18/2018

  LakePharma, Inc., the leading US-based biologics company specializing in antibody & protein engineering, cell line development, and protein production, announced today that their cGMP microBiomanufacturing™ Center is now commercially manufacturing plasmid DNA at their Hopkinton, MA location, which is in close proximity to the Cambridge and Boston areas.  

• LakePharma Expands Antibody Center Into New 40,000 sq. ft. San Carlos Building

  8/15/2018

  LakePharma, the leading US-based biologics company specializing in antibody and protein engineering, cell line development, and protein production, announced today that it has successfully completed moving and consolidating all of its antibody services at its new location at 201 Industrial Rd., San Carlos, CA.

• LakePharma Announces "New Frontiers in Biologics" as The Theme for Its Annual Protein Engineering Symposium in 2018

  8/14/2018

  The Bay Area Annual Event Will Be Held on October 5th at the South San Francisco Conference Center

• 

  ShangPharma Innovation Incubator Expansion Is Taking Strong Root in the Bay Area

  7/13/2018

  In March venture capital firm ShangPharma Innovations announced its plans to expand its life sciences incubator in San Francisco by 40 percent, including state-of-the-art laboratory infrastructure upgrades to its facility.  That investment is paying off as the incubator is growing.

• LakePharma and Harbour Antibodies Announce Partnership for H2L2 Transgenic Mouse Platform for Therapeutic Antibody Discovery

  6/5/2018

  Agreement Provides for Easy Access to H2L2 Platform Use with LakePharma's Discovery and Development Services

• 

  AstraZeneca Opens New Bay Area R&D Site With 400 Employees

  5/24/2018

  After a two-year wait, AstraZeneca finally has employees under one roof in the Bay Area. 

• LakePharma Raises Growth Capital From Summit Partners and Ampersand Capital Partners

  12/13/2017

  The funding will be used to enhance LakePharma's existing service offering and grow the company's biomanufacturing capabilities.

• Hemogenyx Pharma Release: LakePharma Appointed As Service Provider for Lead Drug Development

  11/1/2017

  The relationship between Hemogenyx Pharmaceuticals and LakePharma is designed to have a seamless product development process, from discovery to biomanufacturing

• 

  This is the Fastest-Growing Private Pharma in the Bay Area

  10/30/2017

  Want to work for a company having a growth spurt?

• LakePharma Announces Antibody Collaboration & License Agreement With XOMA

  10/4/2017

• LakePharma Opens New Facility in Bay Area's 'Birthplace of Biotechnology'

  9/13/2017